['diabetes', 'diabetes mellitus, type 2']
['insulin degludec', 'insulin glargine']

        Inclusion criteria: - Male or female, age above or equal to 18 years at the time of signing
        informed consent. - Subjects fulfilling at least one of the below criteria (For this
        inclusion criterion the aim is to include minimum 80% of individuals with a previous
        episode of hypoglycaemia (criterion e). The remaining subjects will have to fulfil at least
        one of criteria a-d.): - a) Experienced at least one severe hypoglycaemic episode within
        the last year (according to the ADA definition, April 2013 (An episode requiring assistance
        of another person to actively administer carbohydrate, glucagon, or take other corrective
        actions. Plasma glucose concentrations may not be available during an event, but
        neurological recovery following the return of plasma glucose to normal is considered
        sufficient evidence that the event was induced by a low plasma glucose concentration.). -
        b) Moderate chronic renal failure, defined as glomerular filtration rate 30 - 59
        mL/min/1.73 m^2 per CKD-EPI by central laboratory analysis. - c) Hypoglycaemic symptom
        unawareness (History of impaired autonomic responses (tremulousness, sweating,
        palpitations, and hunger) during hypoglycaemia). - d) Treated with insulin for more than 5
        years. - e) Episode of hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode
        with low glucose measurement (equal to or below 70 mg/dL [equal to or below 3.9 mmol/L]))
        within the last 12 weeks prior to Visit 1 (screening). - Subjects diagnosed (clinically)
        with type 2 diabetes mellitus. - Treated with basal only insulin (once daily or twice-daily
        insulin (insulin detemir; insulin glargine 100 U/mL, biosimilar of insulin glargine 100
        U/mL or insulin Neutral Protamine Hagedorn)) equal to or above 90 days prior to the day of
        screening with or without any of the following anti-diabetic drugs with stable doses for
        equal to or above 90 days prior to screening: - a) Metformin - b) Dipeptidyl peptidase -4
        inhibitor - c) Sodium-glucose co-transporter 2 inhibitor - d) Alpha-glucosidase-inhibitors
        (acarbose) - e) Thiazolidinediones - f) Marketed oral combination products only including
        the products listed in criteria 5a-5e - HbA1c equal to or below 9.5% (80 mmol/mol) at
        screening by central laboratory analysis. - BMI equal to or below 45 kg/m^2. Exclusion
        Criteria: - Treatment with any medication for the indication of diabetes or obesity other
        than stated in the inclusion criteria in a period of 90 days before the day of screening
      